Simmons & Simmons is advising the Denmark based international biotechnology company Genmab A/S on its proposed acquisition of ProfoundBio, a privately-owned clinical stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, for $1.8 billion, payable in cash at closing.
The transaction was announced on 3 April 2024 in a press release and is expected to close in the first half of 2024, subject to the satisfaction of customary closing conditions.
Under the leadership of Jingyuan Shi, Jenny Liu and other team members from Simmons China offices are supporting this transaction.
The team:
Jingyuan Shi, Ruina Liu, Jenny Liu, Yanyu Lai, Yuchen Lai, Donia Chu, Cecilia Tsang, Rachel Tang